First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC)
Friedl TWP, Krause S, Fasching P, Schneeweiss A, Mueller V, Riethdorf S, Taran FA, Schochter F, Polasik A, Tzschaschel M, De Gregorio A, Meier-Stiegen F, Huober J, Janni W, Fehm T (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: KARGER
City/Town: BASEL
Pages Range: 11-11
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Ulm
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
How to cite
APA:
Friedl, T.W.P., Krause, S., Fasching, P., Schneeweiss, A., Mueller, V., Riethdorf, S.,... Fehm, T. (2020). First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC). In ONCOLOGY RESEARCH AND TREATMENT (pp. 11-11). BASEL: KARGER.
MLA:
Friedl, Thomas W. P., et al. "First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 11-11.
BibTeX: Download